Overview
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It was developed to have an extended half-life compared to natural GHRH, allowing for more sustained growth hormone release and less frequent administration in research settings.
Variants
CJC-1295 exists in two main forms:
- CJC-1295 with DAC (Drug Affinity Complex): Contains a lysine linker that binds to albumin, extending the half-life to approximately 6-8 days
- CJC-1295 without DAC (Modified GRF 1-29): Has a shorter half-life of approximately 30 minutes, requiring more frequent administration
Mechanism of Action
CJC-1295 works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and secretion of growth hormone. Unlike ghrelin mimetics, it does not work through the GHSR receptor.
Research Applications
CJC-1295 has been investigated for:
- Growth hormone deficiency research
- Body composition studies
- Lipodystrophy investigations
- Synergistic combinations with GHRPs
Synergistic Use
In research settings, CJC-1295 is often studied in combination with growth hormone releasing peptides (GHRPs) like ipamorelin, as they work through different receptors and may produce complementary effects.
Research Status
CJC-1295 is a research compound and is not FDA-approved for any medical indication. Clinical trials were conducted but development was discontinued. Use is limited to scientific research.